Eckert & Ziegler: Metzler Initiates Coverage with a Buy Rating and a Price Target of € 21.00. Upside Potential: 41%

Berlin, 14 April 2026. B. Metzler seel. Sohn & Co. AG (Bankhaus Metzler) has started research coverage of Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope-based components for nuclear medicine and measurement technology, with a buy recommendation and a price target of € 21.00. This corresponds to an upside potential of 40.8% compared to the Xetra closing price of € 14.92 on April 13, 2026.

Bankhaus Metzler thus highlights the strong market position of Eckert & Ziegler SE, which is benefiting from rising demand for diagnostic and therapeutic radioisotopes in nuclear medicine.

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com